JPMorgan downgrades Teva as generic medication business struggles

JPMorgan downgrades Teva as generic medication business struggles

Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in some business areas, JPMorgan says. Analyst Chris Schott downgraded the stock to underweight from neutral and lowered his price target to $10 from $11, as he remains unconvinced of a long-term growth story when stacked against other pharmaceutical names. … Read more